IL125491A - Quinoxalinedione compounds, process for their preparation and pharmaceutical compositions containing the same for treating a disease by producing an antagonist effect at a nmda receptor - Google Patents

Quinoxalinedione compounds, process for their preparation and pharmaceutical compositions containing the same for treating a disease by producing an antagonist effect at a nmda receptor

Info

Publication number
IL125491A
IL125491A IL12549197A IL12549197A IL125491A IL 125491 A IL125491 A IL 125491A IL 12549197 A IL12549197 A IL 12549197A IL 12549197 A IL12549197 A IL 12549197A IL 125491 A IL125491 A IL 125491A
Authority
IL
Israel
Prior art keywords
disease
treating
producing
preparation
pharmaceutical compositions
Prior art date
Application number
IL12549197A
Other languages
English (en)
Other versions
IL125491A0 (en
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of IL125491A0 publication Critical patent/IL125491A0/xx
Publication of IL125491A publication Critical patent/IL125491A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12549197A 1996-03-09 1997-02-27 Quinoxalinedione compounds, process for their preparation and pharmaceutical compositions containing the same for treating a disease by producing an antagonist effect at a nmda receptor IL125491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones
PCT/EP1997/000995 WO1997032873A1 (en) 1996-03-09 1997-02-27 Quinoxalinediones

Publications (2)

Publication Number Publication Date
IL125491A0 IL125491A0 (en) 1999-03-12
IL125491A true IL125491A (en) 2003-07-06

Family

ID=10790134

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12549197A IL125491A (en) 1996-03-09 1997-02-27 Quinoxalinedione compounds, process for their preparation and pharmaceutical compositions containing the same for treating a disease by producing an antagonist effect at a nmda receptor

Country Status (42)

Country Link
US (1) US6376490B1 (ja)
EP (1) EP0885212B1 (ja)
JP (1) JP3110467B2 (ja)
KR (1) KR100288099B1 (ja)
CN (1) CN1103770C (ja)
AP (1) AP767A (ja)
AR (1) AR006119A1 (ja)
AT (1) ATE208773T1 (ja)
AU (1) AU717972B2 (ja)
BG (1) BG63340B1 (ja)
BR (1) BR9707851A (ja)
CA (1) CA2248366C (ja)
CO (1) CO4770976A1 (ja)
CZ (1) CZ292792B6 (ja)
DE (1) DE69708269T2 (ja)
DK (1) DK0885212T3 (ja)
DZ (1) DZ2188A1 (ja)
EA (1) EA001730B1 (ja)
ES (1) ES2163742T3 (ja)
GB (1) GB9605027D0 (ja)
HN (1) HN1998000034A (ja)
HR (1) HRP970132A2 (ja)
HU (1) HUP9900975A3 (ja)
ID (1) ID18112A (ja)
IL (1) IL125491A (ja)
IS (1) IS4811A (ja)
MA (1) MA26422A1 (ja)
NO (1) NO984058L (ja)
NZ (1) NZ331060A (ja)
OA (1) OA10850A (ja)
PE (2) PE43398A1 (ja)
PL (1) PL329032A1 (ja)
PT (1) PT885212E (ja)
SI (1) SI0885212T1 (ja)
SK (1) SK283467B6 (ja)
TN (1) TNSN97044A1 (ja)
TR (1) TR199801782T2 (ja)
TW (1) TW454004B (ja)
UY (1) UY24482A1 (ja)
WO (1) WO1997032873A1 (ja)
YU (2) YU39698A (ja)
ZA (1) ZA971987B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE282608T1 (de) * 1997-02-27 2004-12-15 Pfizer Chinoxalindionen
AP982A (en) 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
SK16242002A3 (sk) * 2000-05-19 2003-04-01 Merck Patent Gmbh Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
MY145368A (en) * 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
US7799894B2 (en) 2004-02-06 2010-09-21 Yamaguchi University Electrode for energy storage device and process for producing the same
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
KR20090115951A (ko) 2007-03-01 2009-11-10 프로비오드룩 아게 글루타미닐 사이클라제 저해제의 신규 용도
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2008143019A1 (en) 2007-05-17 2008-11-27 Semiconductor Energy Laboratory Co., Ltd. Triazole derivative, and light-emitting element, light-emitting device, and electronic device with the use of triazole derivative
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US9879004B2 (en) * 2013-02-07 2018-01-30 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556393B1 (en) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
ATE282608T1 (de) * 1997-02-27 2004-12-15 Pfizer Chinoxalindionen

Also Published As

Publication number Publication date
SK121498A3 (en) 2000-10-09
TW454004B (en) 2001-09-11
EP0885212A1 (en) 1998-12-23
HUP9900975A3 (en) 2001-12-28
NO984058L (no) 1998-11-06
EA199800702A1 (ru) 1999-04-29
IS4811A (is) 1998-07-27
PT885212E (pt) 2002-02-28
AU717972B2 (en) 2000-04-06
WO1997032873A1 (en) 1997-09-12
CA2248366C (en) 2002-06-04
TNSN97044A1 (fr) 2005-03-15
NZ331060A (en) 2000-01-28
NO984058D0 (no) 1998-09-03
DE69708269T2 (de) 2002-07-25
PE43398A1 (es) 1998-08-29
UY24482A1 (es) 2000-09-29
AU2023197A (en) 1997-09-22
EA001730B1 (ru) 2001-08-27
OA10850A (en) 2001-08-16
CN1103770C (zh) 2003-03-26
HUP9900975A2 (hu) 1999-07-28
KR19990087614A (ko) 1999-12-27
YU41199A (sh) 2001-09-28
CO4770976A1 (es) 1999-04-30
CZ292792B6 (cs) 2003-12-17
SK283467B6 (sk) 2003-08-05
CN1213369A (zh) 1999-04-07
PE58199A1 (es) 1999-06-11
JP3110467B2 (ja) 2000-11-20
AP767A (en) 1999-09-29
GB9605027D0 (en) 1996-05-08
YU39698A (sh) 1999-03-04
AR006119A1 (es) 1999-08-11
KR100288099B1 (ko) 2001-05-02
BG63340B1 (bg) 2001-10-31
DZ2188A1 (fr) 2002-12-02
TR199801782T2 (xx) 1998-12-21
CZ286498A3 (cs) 1999-07-14
ZA971987B (en) 1998-09-07
CA2248366A1 (en) 1997-09-12
JPH11506123A (ja) 1999-06-02
ES2163742T3 (es) 2002-02-01
PL329032A1 (en) 1999-03-01
AP9700947A0 (en) 1997-04-30
BG102760A (en) 1999-09-30
SI0885212T1 (en) 2002-02-28
ID18112A (id) 1998-03-05
HN1998000034A (es) 1999-02-09
IL125491A0 (en) 1999-03-12
US6376490B1 (en) 2002-04-23
EP0885212B1 (en) 2001-11-14
DK0885212T3 (da) 2002-03-25
HRP970132A2 (en) 1998-06-30
MA26422A1 (fr) 2004-12-20
DE69708269D1 (de) 2001-12-20
ATE208773T1 (de) 2001-11-15
BR9707851A (pt) 1999-07-27

Similar Documents

Publication Publication Date Title
IL125491A (en) Quinoxalinedione compounds, process for their preparation and pharmaceutical compositions containing the same for treating a disease by producing an antagonist effect at a nmda receptor
HUP9603494A3 (en) Hydroxycarboxamide derivatives, pharmaceutical compositions containing them, process for the preparation thereof
HUP9801692A3 (en) Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
HUP0600527A2 (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors, process for their preparation and pharmaceutical compositions containing them
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP9900625A3 (en) Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
HUP9600596A2 (en) Process for producing pharmaceutical compositions containing rapamycin, for treating cardiac inflammatory disease
HUP9603495A3 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, pharmaceutical compositions containing the same and process for their preparation
HUP9602511A2 (en) Aryl-diazinone derivatives, pharmaceutical compositions containing them, and process for producing all these
HUP0201937A3 (en) Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect
HUP0004334A2 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives, process for producing them and pharmaceutical compositions containing them
HUP0101220A3 (en) Nmda receptor antagonist 1-(3-heteroaryl propyl- or-prop-2-enyl)-4-benzylpiperidines, pharmaceutical compositions containing them and process for their preparation
HUP9601034A2 (en) Aryl-alkyl-pyridazinone compounds, process for producing them, and pharmaceutical compositions containing them
HUP9901065A3 (en) New barbituric acid derivatives, pharmaceutical compositions containing these compounds and process for producing them
HUP9900040A3 (en) Tetrahydroquinolines as nmda antagonists, process for producing them and pharmaceutical compositions containing them
HUP0001165A3 (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists, pharmaceutical compositions containing them and process for producing them
HU9802180D0 (en) Process for producing pharmaceutical compositions
HU9701660D0 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, find pharmaceutical compositions containing them
HU9503801D0 (en) Substituted 4-phenyl-thiazol derviatives, process for producing them and pharmaceutical compositions containing them
HU9602640D0 (en) Substituted benzoyl-guanidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9902784A3 (en) Indan-1-ol compounds, process for their preparation and pharmaceutical compositions containing them
HUT73975A (en) Substituted benzol-sulfonyl-ureas and-thioureas, process for producing them, pharmaceutical compositions containing them and their use
HUT73982A (en) Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
HUP9801789A3 (en) Sulfonamide substituted compounds, process for producing them, their use for producing pharmaceutical compositions and pharmaceutical compositions containing said compounds
ZA9711098B (en) Substituted [3H]-benzoxazoles-2-thione and [3H]-benzothiazole-2-thione compounds, a process for their preparation and pharmaceutical compositions containing them.

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees